Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 13, 2016Blood

Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMegan D. HobanForma Therapeutics (United States)Stuart H. OrkinStuart H. OrkinBroad InstituteDBDaniel E. BauerHarvard University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hoban et al. (2016) studied this question.

synapsesocial.com/papers/6a11c070b111c70e786178d1https://doi.org/10.1182/blood-2015-09-618587
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation2008 · 249 citations
  2. 2Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders2012 · 179 citations
  3. 3Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing2011 · 332 citations
  4. 4Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy2001 · 587 citations
  5. 5An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation2007 · 78 citations